Results 311 to 320 of about 271,759 (355)

Clinical Assessment of Walking Capacity in People With Parkinson Disease: Are 2 Minutes Sufficient?

Phys Ther
Johansson H, Rennie L, Grooten WJA, Leavy B.   +3 more
europepmc   +1 more source

Gamification Integration in Technological Devices for Motor Rehabilitation in Parkinson Disease: Scoping Review.

JMIR Serious Games
Bosch-Barceló P, Martínez-Navarro O, Masbernat-Almenara M, Tersa-Miralles C, Pakarinen A, Fernández-Lago H.   +5 more
europepmc   +1 more source

Modernizing the Staging of Parkinson Disease Using Digital Health Technology.

J Med Internet Res
Templeton JM, Poellabauer C, Schneider S, Rahimi M, Braimoh T, Tadamarry F, Margolesky J, Burke S, Al Masry Z.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Parkinson's disease

Neurologic Clinics, 2001
A number of changes have occurred in the management of Parkinson's disease in recent years, with the development of new therapeutic strategies based upon advances in pharmacotherapy and interventional procedures. The treatment of patients with Parkinson's disease is considered here with these advances in mind.
A E, Constantino, L S, Honig
openaire   +5 more sources

Parkinson's Disease and Parkinsonism

The American Journal of Medicine, 2019
Parkinson's disease is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. Male sex and advancing age are independent risk factors and, as the population ages, is taking an increasing toll on productivity and medical resources.
openaire   +2 more sources

Genetics of Parkinson’s disease and parkinsonism

Expert Review of Neurotherapeutics, 2007
The past 10 years has seen a shift in our etiological concepts of Parkinson's disease, moving from a nearly exclusively environmentally mediated disease towards a complex disorder with important genetic contributors. The identification of responsible mutations in certain genes, particularly alpha-synuclein, Parkin, PINK1, DJ-1 and LRRK2, has increased ...
David J Nicholl, Michael R. Douglas, Alistair Lewthwaite   +2 more
openaire   +3 more sources

Parkinson's disease.

Clinical evidence, 2002
Around 1% of adults have Parkinson's disease, with a median time of 9 years between diagnosis and death.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments in people with early-stage Parkinson's disease?
Carl E, Clarke, A Peter, Moore
openaire   +7 more sources

Genetics of Parkinson's disease and parkinsonism

Annals of Neurology, 2006
AbstractUntil 10 years ago, conventional wisdom held that Parkinson's disease was not a genetic disorder. Since that time, there have been a plethora of genetic findings, culminating in the cloning of several genes that derive from the loci given the nomenclature PARK1‐PARK12 (OMIM 168600).
Andrew B. Singleton, Huaiban Cai, John Hardy, Mark R. Cookson, Katrina Gwinn-Hardy   +4 more
openaire   +3 more sources

Identification of parkinsonism and Parkinson's disease

Drugs of Today, 2002
Parkinson's disease is a common movement disorder associated with considerable disability. The clinical syndrome of parkinsonism is based on the presence of core clinical features of rest tremor, bradykinesia, rigidity and impaired postural reflexes or gait.
openaire   +3 more sources

Bradysomnia in Parkinson’s disease

Clinical Neurophysiology, 2016
Polysomnography studies in Parkinson's disease (PD) patients show altered sleep microstructure with decreased level of arousability, indicating impaired sleep-wake dynamics in PD. The aim of this study was to investigate dynamical aspects of sleep EEG in PD as compared to healthy controls.In this retrospective, controlled study, we applied a previously
Imbach, Lukas L, Sommerauer, Michael, Poryazova, Rositsa, Werth, Esther, Valko, Philipp O, Scammell, Thomas E, Baumann, Christian R   +6 more
openaire   +2 more sources